OncoTyrol to Conduct Validation Studies on Protagen UniArray Technology

Jun 10, 2009

NEW YORK (GenomeWeb News) – Protagen said today that it has formed a collaboration with OncoTyrol to conduct validation studies on the firm's UniArray technology platform.

The study aims to determine the "most robust combination of putative prostate cancer markers and optimizing the diagnostic protein biochip to proceed to clinical trials," Protagen CEO Stefan Müllner said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Faster Profiles

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

Standards Needed

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

Conflict Search

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.